Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$10.38 USD

10.38
601,671

+0.05 (0.48%)

Updated Aug 11, 2025 12:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ekta Bagri headshot

4 Top Biotech Stocks to Gain Amid Industry Challenges

by Ekta Bagri

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.

Zacks Equity Research

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.

Zacks Equity Research

Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

by Zacks Equity Research

Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

Zacks Equity Research

Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

by Zacks Equity Research

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

Zacks Equity Research

New Strong Buy Stocks for January 21st

by Zacks Equity Research

ARCB, BCC, DVAX, FCX, and JBHT have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2022.

Zacks Equity Research

Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Dynavax Technologies (DVAX) closed at $14.07, marking a -1.05% move from the previous day.

Zacks Equity Research

Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Dynavax Technologies (DVAX) and Omnicell (OMCL) have performed compared to their sector so far this year.

Ekta Bagri headshot

5 Biotech Stocks That More Than Doubled This Year

by Ekta Bagri

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.

Zacks Equity Research

Dynavax Technologies (DVAX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 20.00% and 40.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dynavax Technologies (DVAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.

Zacks Equity Research

Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data

by Zacks Equity Research

Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.

Zacks Equity Research

Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine

by Zacks Equity Research

Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.

Zacks Equity Research

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 19.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.

Zacks Equity Research

Is a Beat Likely for Moderna (MRNA) This Earnings Season?

by Zacks Equity Research

Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.

Zacks Equity Research

Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.

Zacks Equity Research

Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Dynavax Technologies (DVAX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Dynavax Technologies (DVAX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)

by Zacks Equity Research

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

Zacks Equity Research

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Zacks Equity Research

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Zacks Equity Research

Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data

by Zacks Equity Research

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

Zacks Equity Research

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.